Screener
Aclaris Therapeutics ACRS Pre-Tax Income
Discontinued — last reported Q4 '24
Pre-Tax Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Aclaris Therapeutics’s 10-K, filed February 27, 2025.
- Filed
- Feb 27, 2025
- Fiscal year
- FY2024
- Accession
- 0001558370-25-001819
| Line item | Year Ended / December 31, 2024 | Year Ended / December 31, 2023 |
|---|---|---|
| Interest income | 7,953 | 8,509 |
| Non-cash royalty income | 1,914 | — |
| Total other income | 9,867 | 8,509 |
| Loss before income taxes | (132,065) | (88,848) |
| Income tax benefit | — | (367) |
| Net loss | $(132,065) | $(88,481) |
| Net loss per share, basic and diluted | $(1.71) | $(1.27) |
| Weighted average common shares outstanding, basic and diluted | 77,296,665 | 69,808,855 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Aclaris Therapeutics's pre-tax income?
- Aclaris Therapeutics (ACRS) reported pre-tax income of -$33.02M in Q4 2024.
- How has Aclaris Therapeutics's pre-tax income changed year-over-year?
- Aclaris Therapeutics's pre-tax income decreased by 48.6% year-over-year, from -$22.21M to -$33.02M.
- What is the long-term trend for Aclaris Therapeutics's pre-tax income?
- Over 3 years (2021 to 2024), Aclaris Therapeutics's pre-tax income has grown at a 13.3% compound annual growth rate (CAGR), from -$90.87M to -$132.07M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Aclaris Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude